Glucagon EIA - Cosmo Bio Co.,Ltd.

Antibodies

>

Glucagon EIA

Catalog No.: YII-YK090-EX
Size: 1KIT
Price: ¥76000
$1014
antigen/source: Glucagon
catalog info: Catalog 2012-p111
Storage: 4C
@
Reacts with: Rat
Human
Mouse
Measurement Range: 50 - 10,000 pg/mL
Purpose: This EIA kit is used for quantitative determination of rat, mouse or human pancreatic glucagon in plasma sample. The kit is characterized for sensitive quantification, high specificity and no influence with other components in plasma and needlessness of sample pre-treatment. Glucagon standard used in the kit system is highly purified synthetic product (purity: higher than 98%) and biotinylated pancreatic glucagon is purified by HPLC.
component: Antibody: X
Plate: X
Coating: X
Control: -
Standard: X
Labeling: X
Substrate: X
Others: X
1. Antibody coated plate 1 plate (96 wells)
2. Glucagon standard 1 vial
3. Labeled antigen 1 vial
4. SA-HRP solution 1 bottle (12 mL )
5. Substrate buffer 1 bottle (26 mL )
6. OPD tablet 2 tablets
7. Stopping solution 1 bottle (12 mL )
8. Buffer solution A 1 bottle (10 mL )
9. Buffer solution.. 1 bottle (10 mL )
10. Washing solution 1 bottle (50 mL )
11. Adhesive foil 4 sheets

Other:

 Supplementary 
Competitive
 Applicable sample 
Plasma
[Other]
According to many studies on glucagon immunoassay, it has been established that the antibody against the C-terminal fragment (19-29) of glucagon has specific binding with pancreaticglucagon, whereas the antibody against the N - terminal fragment (1-19) of glucagon has specific binding with both of pancreatic and intestinal glucagon (total glucagon). Once, 30K by Unger et. al had been widely used as an antibody specific for theC- terminal fragment of glucagon, but Nishino, Shima and Yanaihara et. al succeeded in producing pancreatic glucagon specific antibody using synthetic peptide with the Cterminal fragment (19-29) of glucagon as immunogen in 1981. This EIA kit has beendeveloped by using polyclonal antibody against glucagons (19-29), synthetic pancreatic glucagon as glucagon standard and biotinylated pancreatic glucagon as labeled antigen for the measurement of rat, mouse or human glucagon in plasma.


Reference:

•   Takahashi N, Nagamine M, Fukuda M, Motomura W, Abiko A, Haneda M, Fujiya M, Ieko M, Kohgo Y. Case Report Med. 2011;2011:381203.
•  Masuda T, Ohta M, Hirashita T, Kawano Y, Eguchi H, Yada K, Iwashita Y, Kitano S. Obes Surg. 2011 Aug 27.
•  Hira T, Muramatsu M, Okuno M, Hara H. J Nutr Sci Vitaminol (Tokyo). 2011;57(1):30-5.
•  Mochida T, Hira T, Hara H. Endocrinology. 2010 Jul;151(7):3095-104.
•  Hira T, Mochida T, Miyashita K, Hara H. Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G663-71.
•  de Luis DA, Sagrado MG, Conde R, Aller R, Izaola O. J Diabetes Complications. 2009 Jul-Aug;23(4):239-43.
•  Izumi H, Ishizuka S, Inafune A, Hira T, Ozawa K, Shimizu T, Takase M, Hara H. J Nutr. 2009 Jul;139(7):1322-7.
•  Katsura Y, Usui T, Nakao H, Fujimoto S. Endocrinol. 2009 Apr;201(1):151-9.
•  Itou M, Kawaguchi T, TaniguchiE,Sumie S, Oriishi T, Mitsuyama K, Tsuruta O, Ueno T, Sata M. J Gastroenterol Hepatol. 2008 Feb;23(2):244-51.
•  Uehara S, Jung SK, Morimoto R, Arioka S, Miyaji T, Juge N, Hiasa M, Shimizu K, Ishimura A, Otsuka M, Yamamoto A, Maechler P, Moriyama Y. J Neurochem. 2006 Jan;96(2):550-60.
•  HirasawaA, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Nat Med. 2005 Jan;11(1):90-4.
•  J Hepatol. 2011 Jun;54(6):1214-23.
•  J Pharmacol Exp Ther.2010 Aug;334(2):430-8. Epub 2010 May 3.
•  Cell Metab. 2008 Feb;7(2):159-72.
◊  Cell Metab. 2008 Feb;7(2):159-72.
◊  J Pharmacol Exp Ther.2010 Aug;334(2):430-8. Epub 2010 May 3.
◊  J Hepatol. 2011 Jun;54(6):1214-23.
 
>